- Telehealth Visits
- Insurance plan information
Adil I. Daud, MBBS
Cutaneous (Skin) Medical Oncology- Telehealth Visits
- Insurance plan information
Adil I. Daud, MBBS
Cutaneous (Skin) Medical Oncology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Adil Daud, an oncologist, specializes in melanoma and other skin cancers. He is co-director of the Melanoma Center. In addition to caring for patients, he directs research to better understand the biology of melanoma and to develop new treatments. He has developed and led many clinical trials that have expanded the use of gene therapy for melanoma.
Daud earned a medical degree at the Government Medical College, Nagpur. He completed both an internship and a residency in internal medicine at Indiana University School of Medicine, followed by a fellowship in hematology-oncology at Memorial Sloan Kettering Cancer Center. Prior to joining UCSF Medical Center, he was a researcher at the Moffitt Cancer Center in Tampa, Florida, for seven years.
Daud has won numerous awards, including a Young Investigator Award from the American Society of Clinical Oncology and selection as a Castle Connolly Top Doctor.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Hematology - Oncology, Memorial Sloan-Kettering Cancer Center
Residency
- Internal Medicine, Indiana University Hospital
Degree
- MBBS, Government Medical College
My expertise
Specialties
Conditions
Locations
Advanced skin cancer was once a death sentence. Immunotherapy Is changing that.
My research
Clinical trials
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsOpens in a new window
Recruiting
DLTs will be evaluated during the first cycle (21 days) as a single agent (phase 1a monotherapy) or in combination with other agents (phase 1b dose escalation)SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaOpens in a new window
Recruiting
progression-free survival (PFS), centrally assessed (by blinded independent central review) using RECIST 1.1ACTengine® IMA203 Combined With mRNA-4203Opens in a new window
Recruiting
Number of DLTs will be used to determine the maximum tolerated dose (MTD) and/or recommended dose for extension (RDE) after treatment with IMA203 product in co...Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell CarcinomaOpens in a new window
Recruiting
The primary endpoint of this study is to evaluate the pathologic response rate (pathological complete response [pCR] plus major pathological response [MPR])) a...
Publications
Links of interest
Showing 1-6 of 73 reviews
- March 7, 20265 out of 5 Stars
I consider myself very lucky to have this care provider.
- February 5, 20265 out of 5 Stars
Dr Daud was very professional and very personal at the same time.
- January 28, 20265 out of 5 Stars
Dr. Daud is is very caring and has great patient physician communication skills. Caring about the patient is obvious in the interaction.
- January 17, 20265 out of 5 Stars
Dr. Daud always provides compassionate and professional care he is wonderful!
- January 15, 20265 out of 5 Stars
Other than the tardiness of the appointment Dr Daud is the best out there!
- December 27, 20255 out of 5 Stars
Excellent doctor
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.